138,575 results match your criteria with targeted therapies

Proteomic portraits reveal evolutionarily conserved and divergent responses to spinal cord injury.

Mol Cell Proteomics 2021 Jun 12:100096. Epub 2021 Jun 12.

Division of Neurosurgery, University of British Columbia, Vancouver, BC, Canada.

Despite the emergence of promising therapeutic approaches in preclinical studies, the failure of large-scale clinical trials leaves clinicians without effective treatments for acute spinal cord injury (SCI). These trials are hindered by their reliance on detailed neurological examinations to establish outcomes, which inflate the time and resources required for completion. Moreover, therapeutic development takes place in animal models whose relevance to human injury remains unclear. Read More

View Article and Full-Text PDF

Future prospects for mitosis-targeted antitumor therapies.

Biochem Pharmacol 2021 Jun 12:114655. Epub 2021 Jun 12.

Dept. Biochemistry, Molecular and Cell Biology, University of Zaragoza and IIS Aragón, Spain. Electronic address:

Dysregulation of cell cycle progression is a hallmark of cancer cells. In recent years, efforts have been devoted to the development of new therapies that target proteins involved in cell cycle regulation and mitosis. Novel targeted antimitotic drugs include inhibitors of aurora kinase family, polo-like kinase 1, Mps1, Eg5, CENP-5 and the APC/cyclosome complex. Read More

View Article and Full-Text PDF

Paradigm shift in the management of metastatic Non-small Cell Lung Cancer.

Int J Clin Pract 2021 Jun 15:e14533. Epub 2021 Jun 15.

William Beaumont Hospital, Department of Hematology and Medical Oncology, Royal Oak.

Background: Lung cancer is one of the leading causes of cancer mortality in the US. The use of precision medicine in the past 10 years has significantly changed the therapeutic landscape of lung cancer. Management of advanced non-small cell lung cancer (NSCLC) has transitioned from a chemotherapeutic approach to targeted treatments and immunotherapeutic agents. Read More

View Article and Full-Text PDF

All For One, Though Not One For All: Team Players In Normal Tissue Radiobiology.

Int J Radiat Biol 2021 Jun 15:1-61. Epub 2021 Jun 15.

Department of Environmental Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box EHSC, Rochester NY 14642.

: As part of the special issue on 'Women in Science', this review offers a perspective on past and ongoing work in the field of normal (non-cancer) tissue radiation biology, highlighting the work of many of the leading contributors to this field of research. We discuss some of the hypotheses that have guided investigations, with a focus on some of the critical organs considered dose-limiting with respect to radiation therapy, and speculate on where the field needs to go in the future.: The scope of work that makes up normal tissue radiation biology has and continues to play a pivotal role in the radiation sciences, ensuring the most effective application of radiation in imaging and therapy, as well as contributing to radiation protection efforts. Read More

View Article and Full-Text PDF

Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients.

Ann Surg Oncol 2021 Jun 15. Epub 2021 Jun 15.

Department of Surgery, Division of Biological Sciences, The University of Chicago, Chicago, IL, USA.

Background: Adjuvant therapy for stage III melanoma improves several measures of patient survival. However, decisions regarding inclusion of adjuvant therapies in the formularies of public payers necessarily consider the cost-effectiveness of those treatments. The objective of this study is to evaluate the cost-effectiveness of four recently approved adjuvant therapies for BRAF-mutant stage III melanoma in the Medicare patient population. Read More

View Article and Full-Text PDF

Evaluation of Long-Lasting Potential of Suprachoroidal Axitinib Suspension Via Ocular and Systemic Disposition in Rabbits.

Transl Vis Sci Technol 2021 Jun;10(7):19

Clearside Biomedical Inc., Alpharetta, GA, USA.

Purpose: Axitinib, a tyrosine kinase inhibitor, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptors -1, -2 and -3. Suprachoroidal (SC) delivery of axitinib, combined with pan-VEGF inhibition activity of axitinib, has the potential to provide additional benefits compared to the current standard of care with intravitreal anti-VEGF-A agents. This study evaluated the ocular pharmacokinetics and systemic disposition of axitinib after SC administration in rabbits. Read More

View Article and Full-Text PDF

Targeting androgen receptor signaling: a historical perspective.

Endocr Relat Cancer 2021 Jun 1. Epub 2021 Jun 1.

A Zoubeidi, Urologic Sciences, University of British Columbia, Vancouver, V6H 3Z6, Canada.

The first case of prostate cancer was identified by histological examination by J. Adams, a surgeon at The London Hospital, in 1853. In his report, Adams noted that the condition was "a very rare disease". Read More

View Article and Full-Text PDF

Androgen receptor signalling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration sensitive prostate cancer.

Endocr Relat Cancer 2021 Jun 1. Epub 2021 Jun 1.

S Kaochar, Molecular and Cellular Biology, Baylor College of Medicine, Houston, United States.

Based on pioneering work by Huggins, Hodges and others, hormonal therapies have been established as an effective approach for advanced prostate cancer (PC) for the past 8 decades. However, it quickly became evident that androgen deprivation therapy (ADT) via surgical or medical castration accomplishes inadequate inhibition of the androgen receptor (AR) axis, with clinical resistance inevitably emerging due to adrenal and intratumoral sources of androgens and other mechanisms. Early efforts to augment ADT by adding adrenal-targeting agents (aminoglutethimide, ketoconazole) or AR antagonists (flutamide, bicalutamide, nilutamide, cyproterone) failed to achieve overall survival (OS) benefits, although they did exhibit some evidence of limited clinical activity. Read More

View Article and Full-Text PDF

Safety and tolerability of preventive treatment options for chronic migraine.

Expert Opin Drug Saf 2021 Jun 15. Epub 2021 Jun 15.

George Washington University Medical Faculty Associates, 2150 Pennsylvania Ave, NW 7th Floor, Washington, DC 20037.

Introduction: Relative to migraine generally, chronic migraine (CM) imposes greater disability, healthcare utilization and socioeconomic burden. Six therapies currently possess a credible evidence base for prevention/suppression of CM. This review is intended to provide an assessment of their relative utility, defined as a blend of safety, tolerability and efficacy, focusing in particular on their safety and tolerability. Read More

View Article and Full-Text PDF

Tissue-specific therapy in immune-mediated kidney diseases: new ARGuments for targeting the IL-23/IL-17 axis.

J Clin Invest 2021 Jun;131(12)

Division of Translational Immunology, III. Department of Medicine.

Immune-mediated kidney diseases are a leading cause of end-stage renal disease. Despite recent discoveries, the immunopathogenesis of this heterogeneous disease group remains incompletely understood, which is a major reason for the lack of specific therapies and targeted interventions. Accumulating evidence suggests that cytokines related to the T cell response play an important role in renal autoimmunity. Read More

View Article and Full-Text PDF

Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells.

Oncogene 2021 Jun 14. Epub 2021 Jun 14.

Institute of Biomedicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.

Treatment of prostate cancer confronts resistance to androgen receptor (AR)-targeted therapies. AR-associated coregulators and chromatin proteins hold a great potential for novel therapy targets. Here, we employed a powerful chromatin-directed proteomics approach termed ChIP-SICAP to uncover the composition of chromatin protein network, the chromatome, around endogenous AR in castration resistant prostate cancer (CRPC) cells. Read More

View Article and Full-Text PDF

Pediatric sepsis biomarkers for prognostic and predictive enrichment.

Hector R Wong

Pediatr Res 2021 Jun 14. Epub 2021 Jun 14.

Cincinnati Children's Hospital Medical Center and Cincinnati Children's Research Foundation, Cincinnati, OH, USA.

Sepsis is a major public health problem in children throughout the world. Given that the treatment guidelines emphasize early recognition, there is interest in developing biomarkers of sepsis, and most attention is focused on diagnostic biomarkers. While there is a need for ongoing discovery and development of diagnostic biomarkers for sepsis, this review will focus on less well-known applications of sepsis biomarkers. Read More

View Article and Full-Text PDF

Identification of transdiagnostic psychiatric disorder subtypes using unsupervised learning.

Neuropsychopharmacology 2021 Jun 14. Epub 2021 Jun 14.

Max Planck Institute of Psychiatry, Munich, Germany.

Psychiatric disorders show heterogeneous symptoms and trajectories, with current nosology not accurately reflecting their molecular etiology and the variability and symptomatic overlap within and between diagnostic classes. This heterogeneity impedes timely and targeted treatment. Our study aimed to identify psychiatric patient clusters that share clinical and genetic features and may profit from similar therapies. Read More

View Article and Full-Text PDF

Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells.

J Immunother Cancer 2021 Jun;9(6)

Immunotherapy and Innovative Therapeutics Unit, Medical Oncology and Hematology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

We previously published the results of a pilot study showing that vaccination with tumor-loaded dendritic cells (DCs) induced both T and B cell response and produced clinical benefit in the absence of toxicity in patients with relapsed, indolent non-Hodgkin lymphoma (iNHL). The purpose of the present short report is to provide a 15-year follow-up of our study and to expand the biomarker analysis previously performed. The long-term follow-up highlighted the absence of particular or delayed toxicity and the benefit of active immunization with DCs loaded with autologous, heat-shocked and UV-C treated tumor cells in relapsed iNHL (5-year and 10-year progression-free survival (PFS) rates: 55. Read More

View Article and Full-Text PDF

Palliative Radiotherapy for Diffuse Large B-cell Lymphoma.

Clin Lymphoma Myeloma Leuk 2021 May 19. Epub 2021 May 19.

Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.

Recent improvements in chemoimmunotherapies, targeted agents, hematopoietic stem cell transplants, and cellular therapies have revolutionized treatment paradigms for patients with diffuse large B-cell lymphoma (DLBCL). Even in the relapsed or refractory setting, contemporary treatment options are delivered with curative intent and can lead to lasting remissions. Although such therapies have improved overall outcomes, they have increasingly led to a wide variety of presentations of recurrent tumors in need of palliation. Read More

View Article and Full-Text PDF

EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer.

Clin Lung Cancer 2021 May 16. Epub 2021 May 16.

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia. Electronic address:

Background: Epidermal growth factor receptor gene (EGFR) exon 20 insertion (ex20-ins) mutations are an uncommon and heterogeneous group of non-small cell lung cancers (NSCLCs), resistant to conventional EGFR tyrosine kinase inhibitors (TKIs). Characteristics and outcomes of patients with EGFR ex20-ins have not been fully established; we sought to clarify them using a multinational patient database.

Patients And Methods: Patients with NSCLC from six Australian institutions with EGFR exon 20 mutations (ex20-mut), excluding T790M, were retrospectively reviewed. Read More

View Article and Full-Text PDF

The Challenge of Managing Patients Suffering from TBI: The Utility of Multiparametric MRI.

CNS Spectr 2021 Apr;26(2):178-179

Western University of Health Sciences, Pomona, CA, USA.

Traumatic brain injury (TBI) is a complex phenomenon affecting multiple areas of the brain in multiple ways. Both right and left hemispheres are affected as well as supratentorial and infratentorial compartments. These multifocal injuries are caused by many factors including acute mechanical injury, focal intracranial hemorrhage, blunt and rotational forces, epidural and subdural hematoma, hypoxemia, hypotension, edema, axonal damage, neuronal death, gliosis and blood brain barrier disruption. Read More

View Article and Full-Text PDF

Circular RNA hsa_circ_0044234 as distinct molecular signature of triple negative breast cancer: a potential regulator of GATA3.

Cancer Cell Int 2021 Jun 14;21(1):312. Epub 2021 Jun 14.

Medical Genetic Ward, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Dr. Qarib St, Keshavarz Blvd, Tehran, Iran.

Background: Circular RNAs (circRNAs) have been implicated in the initiation and development of breast cancer as functional non-coding RNAs (ncRNA). The roles of circRNAs as the competing endogenous RNAs (ceRNAs) to sponge microRNAs (miRNAs) have also been indicated. However, the functions of circRNAs in breast cancer have not been totally elucidated. Read More

View Article and Full-Text PDF

Targeted and modular architectural polymers employing bioorthogonal chemistry for quantitative therapeutic delivery.

Chem Sci 2020 Mar 6;11(12):3268-3280. Epub 2020 Mar 6.

Centre for Advanced Imaging, The University of Queensland Brisbane QLD 4072 Australia

There remain several key challenges to existing therapeutic systems for cancer therapy, such as quantitatively determining the true, tissue-specific drug release profile , as well as reducing side-effects for an increased standard of care. Hence, it is crucial to engineer new materials that allow for a better understanding of the pharmacokinetic/pharmacodynamic behaviours of therapeutics. We have expanded on recent "click-to-release" bioorthogonal pro-drug activation of antibody-drug conjugates (ADCs) to develop a modular and controlled theranostic system for quantitatively assessing site-specific drug activation and deposition from a nanocarrier molecule, by employing defined chemistries. Read More

View Article and Full-Text PDF

Epithelial wound healing in inflammatory bowel diseases: the next therapeutic frontier.

Transl Res 2021 Jun 11. Epub 2021 Jun 11.

Department of Medicine, The University of Chicago, Chicago, IL USA. Electronic address:

Patients with one of the many chronic inflammatory disorders broadly classified as inflammatory bowel disease (IBD) now have a diverse set of immunomodulatory therapies at their disposal. Despite these recent medical advances, complete sustained remission of disease remains elusive for most patients. The full healing of the damaged intestinal mucosa is the primary goal of all therapies. Read More

View Article and Full-Text PDF

Targeting the mercapturic acid pathway for the treatment of melanoma.

Cancer Lett 2021 Jun 11. Epub 2021 Jun 11.

Department of Medical Oncology, Beckman Research Institute, City of Hope Comprehensive Cancer Center and National Medical Center, Duarte, CA, 91010, USA.

The treatment of metastatic melanoma is greatly hampered by the simultaneous dysregulation of several major signaling pathways that suppress apoptosis and promote its growth and invasion. The global resistance of melanomas to therapeutics is also supported by a highly active mercapturic acid pathway (MAP), which is responsible for the metabolism and excretion of numerous chemotherapy agents. The relative importance of the MAP in melanoma survival was not recognized until demonstrated that B16 melanoma undergoes dramatic apoptosis and regression upon the depletion or inhibition of the MAP transporter protein RLIP. Read More

View Article and Full-Text PDF

Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus.

J Invest Dermatol 2021 Jun 11. Epub 2021 Jun 11.

Department of Dermatology, Duke University Medical Center, Durham, NC USA.

Pemphigus is a debilitating immunoglobulin G (IgG)-mediated autoimmune disease in need of better tolerated, more targeted and rapid onset therapies. ALXN1830 is a humanized IgG4 antibody that blocks neonatal Fc receptor (FcRn) interactions with IgG. A multicenter, open-label safety and tolerability phase 1b/2 trial (NCT03075904) was conducted in North America from July 2017 to January 2019 and included patients aged ≥ 18 years with a confirmed diagnosis of pemphigus (vulgaris or foliaceus) and active disease. Read More

View Article and Full-Text PDF

Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies.

JCO Oncol Pract 2021 Jun 14:OP2100177. Epub 2021 Jun 14.

Division of Medical Oncology, Mayo Clinic, Rochester, MN.

Purpose: The benefit of routine pre-emptive screening for severe acute respiratory syndrome coronavirus 2 infections in patients with cancer before cancer-directed therapies is unclear. Herein, we characterize the outcomes of a cohort of patients with cancer who were diagnosed with COVID-19 by routine screening (RS) in comparison with those diagnosed on the basis of clinical suspicion or exposure history (nonroutine screening [NRS]).

Methods: A multisite prospective observational study was conducted at three major and five satellite campuses of the Mayo Clinic Cancer Center between March 18 and July 31, 2020. Read More

View Article and Full-Text PDF

Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant.

Curr Oncol Rep 2021 Jun 14;23(8):95. Epub 2021 Jun 14.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Purpose Of Review: Over the past two decades, tyrosine kinase inhibitors (TKIs) have changed the management of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), and this has led to significant improvement in their outcome. In this review, we will provide an overview of the current understanding of treatment of Ph+ ALL focusing on TKIs, alloHSCT, and novel therapies.

Recent Findings: The advent of more potent TKIs and the novel therapeutic options including blinatumomab, inotuzumab ozogamicin, and CD19 CAR-T therapy has changed the role of allogeneic hematopoietic stem cell transplant (alloHSCT) and intensive chemotherapy. Read More

View Article and Full-Text PDF

Frontline Maintenance Treatment for Ovarian Cancer.

Curr Oncol Rep 2021 Jun 14;23(8):97. Epub 2021 Jun 14.

UCL Cancer Institute, University College CRUK and UCL Cancer Trials Centre, London, WC1E 6DD, UK.

Purpose Of Review: Advanced epithelial ovarian cancer remains the most lethal gynaecological cancer. Most patients with advanced disease will relapse within 3 years after primary treatment with surgery and chemotherapy. Recurrences become increasing difficult to treat due to the emergence of drug resistance and 5-year survival has changed little over the last decade. Read More

View Article and Full-Text PDF

ROS1 Targeted Therapies: Current Status.

Curr Oncol Rep 2021 Jun 14;23(8):94. Epub 2021 Jun 14.

Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, 12801 E 17th Ave, 1665 Aurora Court, Colorado, AU, USA.

Purpose Of Review: Molecular drivers are increasingly identified as therapeutic targets for non-small cell lung cancer (NSCLC). This review focuses on the role of ROS1 inhibitors in treating relapsed/metastatic ROS-1 altered (ROS1+) NSCLC.

Recent Findings: Four FDA-approved drugs have significant activity against ROS1+ NSCLC: crizotinib, ciritinib, lorlatinib, and entrectinib. Read More

View Article and Full-Text PDF

3D-Printed Drug Capture Materials Based on Genomic DNA Coatings.

ACS Appl Mater Interfaces 2021 Jun 14. Epub 2021 Jun 14.

Division of Engineering and Applied Science, California Institute of Technology, Pasadena, California 91125, United States.

The toxic side effects of chemotherapy have long limited its efficacy, prompting expensive and long-drawn efforts to develop more targeted cancer therapeutics. An alternative approach to mitigate off-target toxicity is to develop a device that can sequester chemotherapeutic agents from the veins that drain the target organ before they enter systemic circulation. This effectively localizes the chemotherapy to the target organ, minimizing any hazardous side effects. Read More

View Article and Full-Text PDF

Remodeling tumor microenvironment with nanomedicines.

Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021 Jun 14:e1730. Epub 2021 Jun 14.

Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.

The tumor microenvironment (TME) has been recognized as a major contributor to cancer malignancy and therapeutic resistance. Thus, strategies directed to re-engineer the TME are emerging as promising approaches for improving the efficacy of antitumor therapies by enhancing tumor perfusion and drug delivery, as well as alleviating the immunosuppressive TME. In this regard, nanomedicine has shown great potential for developing effective treatments capable of re-modeling the TME by controlling drug action in a spatiotemporal manner and allowing long-lasting modulatory effects on the TME. Read More

View Article and Full-Text PDF

Appraisals of the Bangladeshi Medicinal Plant Used by Folk Medicine Practitioners in the Management of COVID-19: A Biochemical and Computational Approach.

Front Mol Biosci 2021 26;8:625391. Epub 2021 May 26.

Department of Pharmacy, BGC Trust University Bangladesh, Chittagong, Bangladesh.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first recognized in Wuhan in late 2019 and, since then, had spread globally, eventually culminating in the ongoing pandemic. As there is a lack of targeted therapeutics, there is certain opportunity for the scientific community to develop new drugs or vaccines against COVID-19 and so many synthetic bioactive compounds are undergoing clinical trials. In most of the countries, due to the broad therapeutic spectrum and minimal side effects, medicinal plants have been used widely throughout history as traditional healing remedy. Read More

View Article and Full-Text PDF

Functional Genomics for Undiagnosed Patients: The Impact of Small GTPases Signaling Dysregulation at Pan-Embryo Developmental Scale.

Front Cell Dev Biol 2021 25;9:642235. Epub 2021 May 25.

Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.

While individually rare, disorders affecting development collectively represent a substantial clinical, psychological, and socioeconomic burden to patients, families, and society. Insights into the molecular mechanisms underlying these disorders are required to speed up diagnosis, improve counseling, and optimize management toward targeted therapies. Genome sequencing is now unveiling previously unexplored genetic variations in undiagnosed patients, which require functional validation and mechanistic understanding, particularly when dealing with novel nosologic entities. Read More

View Article and Full-Text PDF